Investor Alert

Aug. 17, 2022, 8:56 a.m. EDT

Ocumetics announces Frankfurt Stock Exchange listing

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Aug 17, 2022 (TheNewswire.ca via COMTEX) -- (via TheNewswire)

Calgary, Alberta - TheNewswire - August 17, 2022 - Ocumetics Technology Corp. ("Ocumetics" or the "Company") (TSXV:OTC) (fra:2QBO) is pleased to announce that its common shares have commenced trading on the Frankfurt Stock Exchange under the symbol "2QBO". The Company's common shares will continue to trade on the TSX Venture Exchange under the symbol "OTC".

The Company has listed on the Frankfurt Stock Exchange to provide greater trading visibility and convenience for international investors, resulting in more liquidity and greater reach.

"The appeal of our adaptive intraocular lens technology to international investors, and numerous requests from those investors, motivated us to pursue this listing," said Dr. Mark Lee, CEO of Ocumetics. "We look forward to increasing our base of international investors and sharing development progress of our accommodating intraocular lens with this group", adds Dr. Lee.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (fra:2QBO) is a Canadian research and product development company that specializes in adaptive lens designs. Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Ocumetics has developed an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near.


Dr. Mark Lee

President and CEO

(604) 832-6052

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2022 TheNewswire - All rights reserved.


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.